BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20031628)

  • 1. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
    Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
    Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
    Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
    Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity.
    Nie XY; Li JL; Zhang Y; Xu Y; Yang XL; Fu Y; Liang GK; Lu Y; Liu J; Shi LW
    J Zhejiang Univ Sci B; 2017 Jan.; 18(1):37-47. PubMed ID: 28070995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
    Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions.
    Rudez G; Pons D; Leebeek F; Monraats P; Schrevel M; Zwinderman A; de Winter R; Tio R; Doevendans P; Jukema W; de Maat M
    Hum Mutat; 2008 Mar; 29(3):375-80. PubMed ID: 18175333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
    Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
    Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2009 Nov; 124(5):588-91. PubMed ID: 19631365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.
    Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS
    Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Dupont A; Gaussem P; Storey RF
    Platelets; 2005 Sep; 16(6):340-5. PubMed ID: 16194864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor.
    Bouman HJ; van Werkum JW; Rudez G; Leebeek FW; Kruit A; Hackeng CM; Ten Berg JM; de Maat MP; Ruven HJ
    Thromb Haemost; 2010 Feb; 103(2):379-86. PubMed ID: 20126830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
    Perez de Prado A; Cuellas C; Diego A; de Miguel A; Samaniego B; Alonso-Orcajo N; Carbonell R; Pascual C; Fernandez-Vazquez F; Calabozo RG
    Thromb Res; 2009 Dec; 124(6):678-82. PubMed ID: 19411094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
    Bonello L; Bonello-Palot N; Armero S; Bonello C; Mokhtar OA; Arques S; Dignat-George F; Camoin-Jau L; Paganelli F
    Thromb Res; 2010 Apr; 125(4):e167-70. PubMed ID: 19914687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.
    Galić E; Vrbanić L; Kapitanović S; Catela Ivković T; Petro D; Vuković I; Bsharat RS; Milicević Z; Vcev A; Mirat J
    Coll Antropol; 2013 Jun; 37(2):491-8. PubMed ID: 23940995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.